263 related articles for article (PubMed ID: 26369687)
1. Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between H. pylori Infection and Low-Dose Aspirin Use.
Iijima K; Shimosegawa T
Curr Pharm Des; 2015; 21(35):5056-65. PubMed ID: 26369687
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy.
Iwamoto J; Saito Y; Honda A; Matsuzaki Y
World J Gastroenterol; 2013 Mar; 19(11):1673-82. PubMed ID: 23555156
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin.
Hsu PI; Tsai TJ
Curr Pharm Des; 2015; 21(35):5049-55. PubMed ID: 26369688
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Pilotto A; Franceschi M; Longoa MG; Scarcelli C; Orsitto G; Perri FC; D'Ambrosio LP; Leandro G
Dig Liver Dis; 2004 Oct; 36(10):666-70. PubMed ID: 15506665
[TBL] [Abstract][Full Text] [Related]
5. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice.
Leung Ki EL; Chan FK
Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):163-72. PubMed ID: 22542154
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for gastrointestinal bleeding associated with low-dose aspirin.
Valkhoff VE; Sturkenboom MC; Kuipers EJ
Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):125-40. PubMed ID: 22542151
[TBL] [Abstract][Full Text] [Related]
7. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study.
Uemura N; Sugano K; Hiraishi H; Shimada K; Goto S; Uchiyama S; Okada Y; Origasa H; Ikeda Y;
J Gastroenterol; 2014 May; 49(5):814-24. PubMed ID: 23754512
[TBL] [Abstract][Full Text] [Related]
8. [Risk and prevention of gastrointestinal complications due to low-dose aspirin and other antiplatelet agents].
Bretagne JF
Rev Prat; 2008 Sep; 58(13):1434-6, 1439-40. PubMed ID: 18924327
[TBL] [Abstract][Full Text] [Related]
9. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
Lanas A; Scheiman J
Curr Med Res Opin; 2007 Jan; 23(1):163-73. PubMed ID: 17257477
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of gastroduodenal complications in patients taking low-dose aspirin].
Chryssostalis A; Marck G; Sibilia J; Chaussade S
Gastroenterol Clin Biol; 2004 Apr; 28 Spec No 3():C84-9. PubMed ID: 15366679
[TBL] [Abstract][Full Text] [Related]
11. [Digestive complications of aspirin].
Hochain P; Capet C; Colin R
Rev Med Interne; 2000 Mar; 21 Suppl 1():50s-59s. PubMed ID: 10763205
[TBL] [Abstract][Full Text] [Related]
12. Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.
Lanas A; Gargallo CJ
J Gastroenterol; 2015 Jun; 50(6):626-37. PubMed ID: 25595209
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of Peptic Ulcer Associated with Aspirin and Antiplatelet Agent].
Ahn JY
Korean J Gastroenterol; 2020 Nov; 76(5):238-241. PubMed ID: 33234770
[TBL] [Abstract][Full Text] [Related]
14. Anti-platelet therapy and managing ulcer risk.
Chan FK
J Gastroenterol Hepatol; 2012 Feb; 27(2):195-9. PubMed ID: 22142030
[TBL] [Abstract][Full Text] [Related]
15. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
Limmer S; Ittel TH; Wietholtz H
Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
[TBL] [Abstract][Full Text] [Related]
16. [Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori].
Schneider AR; Armbruster S; Mann J; von Römer W; Schuster T; Schepp W
Z Gastroenterol; 2012 Nov; 50(11):1156-60. PubMed ID: 23150107
[TBL] [Abstract][Full Text] [Related]
17. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
[TBL] [Abstract][Full Text] [Related]
18. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors.
Venerito M; Schneider C; Costanzo R; Breja R; Röhl FW; Malfertheiner P
Aliment Pharmacol Ther; 2018 Jun; 47(11):1464-1471. PubMed ID: 29655196
[TBL] [Abstract][Full Text] [Related]
19. Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users.
Papatheodoridis GV; Archimandritis AJ
World J Gastroenterol; 2005 Jul; 11(25):3811-6. PubMed ID: 15991274
[TBL] [Abstract][Full Text] [Related]
20. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
Hsu PI
J Gastroenterol Hepatol; 2012 Apr; 27(4):654-61. PubMed ID: 22283743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
